Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. (WUXAY) is a global leader in pharmaceutical R&D and manufacturing services, providing critical support for drug discovery through its integrated CRDMO and CTDMO platforms. This news hub offers investors and industry professionals centralized access to essential updates shaping the company's position in life sciences innovation.
Track official press releases covering clinical trial milestones, regulatory approvals, and strategic partnerships. Our curated news collection includes earnings reports, manufacturing capacity expansions, and technological advancements across small-molecule and biologics development. Key updates span: quarterly financial results, global facility certifications, novel therapy collaborations, and operational efficiency initiatives.
This resource enables stakeholders to monitor WuXi AppTec's progress in accelerating drug development timelines while maintaining compliance with international quality standards. Regular updates reflect the company's role in enabling cost-effective solutions for 6,000+ clients across 30 countries.
Bookmark this page for real-time notifications on material developments impacting pharmaceutical services markets. Combine these updates with fundamental analysis tools available through Stock Titan for comprehensive investment decision-making.
WuXi AppTec reported financial results for the first half of 2024. Revenue for Q2 2024 was RMB9,259 million, up 16.0% QoQ. Adjusted non-IFRS net profit increased by 28.5% QoQ to RMB4,372 million. For H1 2024, revenue excluding COVID-19 projects was RMB17,241 million, down 0.7% YoY, with an adjusted gross profit margin of 39.8%. The net profit attributable to shareholders was RMB4,240 million. Operating cash flow grew 48.3% YoY. The company added over 500 new customers and achieved a backlog of RMB43.10 billion, up 33.2% YoY. WuXi Chemistry recorded H1 revenue of RMB12.21 billion, growing 2.1% YoY. TIDES business revenue grew 57.2% YoY. WuXi Testing saw a 5.4% decline in lab testing revenue. WuXi ATU revenue dropped 19.4% YoY due to U.S. legislation impacts. For the full year, WuXi AppTec aims for revenue between RMB38.3-40.5 billion and free cash flow of RMB4-5 billion.
WuXi AppTec reported a 5.8% increase in revenue year-over-year, reaching
WuXi AppTec reported a 71.8% increase in revenue year-over-year, reaching RMB39,355 million for 2022. Their net profit attributable to owners grew 72.9% to RMB8,814 million, with diluted EPS rising 63.0% to RMB2.82. The adjusted non-IFRS net profit surged 83.2% to RMB9,399 million. Operating cash flow improved by 133.6% to RMB10,230 million, with free cash flow turning positive. A cash dividend of RMB2,644 million will be distributed, constituting 30% of 2022 net profit. Despite challenges from COVID-19, WuXi expanded its customer base to over 5,950 active accounts, driving strong performance in its CRDMO and CTDMO business models.
FAQ
What is the current stock price of Wuxi Apptec (WUXAY)?
What is the market cap of Wuxi Apptec (WUXAY)?
